Lonza Group Ltd

Lonza Group Ltd Earnings Recaps

LONN.SW Health Care 1 recap
Q2 2026 Jul 24, 2026

Lonza’s shares fell 3.9% following the earnings release, reflecting investor disappointment with a cautious outlook despite solid H1 performance and margin gains.

Key takeaways
  • Reported H1 sales of CHF 3.4 billion, with 16% constant exchange rate (CER) growth and CORE EBITDA margin expansion to 34.8%, up 4.4 percentage points year-over-year.
  • Free cash flow improved by CHF 300 million compared to H1 2025, supported by operational execution and cost discipline.
  • Upgraded full-year CORE EBITDA margin guidance to 33%-34% and confirmed CER sales growth guidance of 11%-12%, signaling measured optimism.
  • Broad-based double-digit CER sales growth across all three business platforms, including 22.6% growth in Specialized Modalities.
  • Market reaction suggests investor concern over the outlook and possibly the tempered H2 expectations despite strong reported fundamentals.